Advertisement
Screener

NASDAQ:MGX | Increase (Decrease) in Deferred Revenue | Metagenomi Therapeutics, Inc.

0.1 / 5 stars · 3/120 Roast Me

Metagenomi Therapeutics, Inc. Increase (Decrease) in Deferred Revenue

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2026-08-10

  • Metagenomi Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2026-06-30 was $257.00K.
  • Metagenomi Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2026-03-31 was -$748.00K.
  • Metagenomi Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2025-06-30 was -$7.37M.
  • Metagenomi Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2025-03-31 was -$3.05M.
Period endIncrease (Decrease) in Deferred Revenue 3 monthIncrease (Decrease) in Deferred Revenue 6 month
2026-06-30$257.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10
-$491.00K
10-Q · filed 2026-08-10
2026-03-31-$748.00K
10-Q · filed 2026-05-11
2025-06-30-$7.37M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10
-$10.42M
10-Q · filed 2026-08-10
2025-03-31-$3.05M
10-Q · filed 2026-05-11